Determination of oxycodone in plasma and identification of a major metabolite
β Scribed by Stephen H. Weinstein; Janet C. Gaylord
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- English
- Weight
- 268 KB
- Volume
- 68
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
β¦ Synopsis
An electron-capture GLC method is described for oxycodone and its major metabolite, noroxycodone, in plasma and urine. The method involves extraction of the two substances into benzene-isopropranol at pH 10.4, followed by back-extraction into 0.1 N HCl. The acid phase is washed with hexane and made alkaline prior to reextraction into benzene-isopropanol. The solvent is removed by evaporation, and the heptafluorobutyryl derivatives of the test substances are formed. After removal of excess reagent, oxycodone and noroxycodone are quantitated by GLC. The characteristics of both substances, with respect to plasma levels in dogs and analgesic activity in mice, are reported. Isolation of noroxycodone from human urine and its identification by TLC, GLC, and mass spectrometry are described.
π SIMILAR VOLUMES
Two rapid, sensitive, and specific gas chromatographic (GC) methods for the quantitative determination of quazepam (I), 7-chloro-5-(2fluorophenyl-1,3-dihydro-1 -(2,2,2-trifluoroethyl)-2H -1,4-benzodiazepine-Zthione, and its major active plasma metabolites, the 2-0x0 compound (11) and the dealkylated
A high-performance liquid chromatographic method using a fluorometric detector was developed for the determination of plasma concentrations of the antidepressant indalpine (I) and its major metabolite 4-[2-(3-indolyl)ethyl]-2-piperidinone (PK). the same procedure was used to measure, in urine, level
Urine samples taken from a person who ingested nortriptyline.HC1 (4 X 25 mg. daily) were extracted by a two-phase procedure with ether. A first screening by UV spectrophotometry showed the presence of compound(s) with basic character but different from free nortriptyline. The TLC separation of aliqu